VNL1 Stock Chart & Stats
€0.03
<€0.01(7.69%)
At close: 4:00 PM EST
€0.03
<€0.01(7.69%)
Day’s Range― - ―
52-Week Range<€0.01 - €0.04
Previous CloseN/A
Volume0.00
Average Volume (3M)1.33K
Market Cap
€8.75M
Enterprise Value€52.71
Total Cash (Recent Filing)€25.16M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta-0.15
Next Earnings
Mar 30, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding995,351,700
10 Day Avg. Volume4,000
30 Day Avg. Volume1,333
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)2.36
Price to Sales (P/S)4.69
P/FCF Ratio14.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetA debt-free structure reduces interest obligations and refinancing exposure, preserving financial flexibility through difficult operating periods. It also gives management more room to direct available capital toward operations or recovery initiatives without servicing a leveraged balance sheet.
Improved Cash GenerationRecent positive operating and free cash flow indicates stronger cash discipline despite reported accounting losses. If maintained, internally generated cash can support working needs and reduce reliance on external funding, although the improvement remains exposed to recent volatility.
Higher Gross MarginThe sharp gross-margin improvement suggests better economics at the gross-profit level and could provide a stronger base for recovery if sustained. This benefit is meaningful because higher gross profit gives the company more capacity to absorb operating costs over time.
Bears Say
Persistent LossesMulti-year losses and a deeply negative net margin show that the business has not converted revenue into sustainable earnings. Continued losses can consume capital, restrict reinvestment capacity, and make any operating improvement dependent on a credible turnaround.
Eroding Equity BaseMaterial equity erosion indicates that cumulative losses are weakening the company’s capital base despite its lack of debt. Negative returns on equity further show that shareholder capital is currently being used inefficiently, reducing resilience if losses continue.
Volatile Cash GenerationRecent positive cash flow is offset by a sharp 2025 free-cash-flow decline and a history of negative operating cash flow. This volatility makes internally funded growth less dependable and raises execution risk even with a conservatively financed balance sheet.
VNL1 FAQ
What was China Health Group Inc.’s price range in the past 12 months?
China Health Group Inc. lowest stock price was <€0.01 and its highest was €0.04 in the past 12 months.
What is China Health Group Inc.’s market cap?
China Health Group Inc.’s market cap is €8.75M.
When is China Health Group Inc.’s upcoming earnings report date?
China Health Group Inc.’s upcoming earnings report date is Mar 30, 2027 which is in 203 days.
How were China Health Group Inc.’s earnings last quarter?
China Health Group Inc. released its earnings results on Aug 27, 2026. The company reported €0.001 earnings per share for the quarter.
Is China Health Group Inc. overvalued?
According to Wall Street analysts China Health Group Inc.’s price is currently Overvalued.
Does China Health Group Inc. pay dividends?
China Health Group Inc. does not currently pay dividends.
What is China Health Group Inc.’s EPS estimate?
China Health Group Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does China Health Group Inc. have?
China Health Group Inc. has 995,351,700 shares outstanding.
What happened to China Health Group Inc.’s price movement after its last earnings report?
China Health Group Inc. reported an EPS of €0.001 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of China Health Group Inc.?
Currently, no hedge funds are holding shares in DE:VNL1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
China Health Group Inc.
China Health Group Inc., an investment holding company, researches and develops drugs, bio drugs, natural drugs, and synthetic drugs in the People’s Republic of China. The company offers contracted pharmaceutical development and clinical research, and post market; and post launch market research, medical science, and medical market services. It also provides hospital management, clinical research and promotion, rehabilitation tourism, and specialty hospital services, as well as Wanquan cloud health services. In addition, the company offers pharmacodynamics and clinical research of drugs. China Health Group Inc. was formerly known as Venturepharm Laboratories Limited and changed its name to China Health Group Inc. in January 2015. The company was founded in 1998 and is headquartered in Beijing, China.
Technical Analysis
Hangzhou Tigermed Consulting Co., Ltd. Class H
―
WuXi AppTec Co., Ltd. Class H
―
JOINN Laboratories (China) Co., Ltd. Class H
―
Mega Genomics Limited
―
Biosino Bio-Technology & Science, Inc. Class H
―